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 ABSTRACT 
 
Glycosylation has profound impacts in many biological processes, such as immune 
response, inflammation, cell- cell communication, and host- pathogen interaction. The 
importance of glycosylation is further accentuated as more than 70% of approved protein-based 
drugs are asparagine-linked (N-linked) glycoproteins. In many cases, the efficacy, safety, and 
stability of glycoprotein drugs are dictated by its glycan structure. Despite its importance, 
advancement in glycoscience and glycoengineering is hindered, largely due to insufficient 
understanding of glycan biosynthesis and bioprocess, as well as, a lack of platform for producing 
homogeneous designed glycan structures on proteins. Current glycoprotein expression 
platforms, such as using Chinese hamster ovary (CHO) cell line, cannot avoid heterogeneous 
glycoform with high batch to batch variability due to their endogenous glycosylation pathways 
that are sensitive to a change in culture environment. Moreover, the complexity of metabolic 
network inside cells has made it difficult to understand and engineer specific glycosylation 
pathways to produce designer glycoproteins. To address those challenges systematically, we 
proposed to integrate experimental and mathematical methods, such as E. coli- based cell free 
glycoprotein synthesis (CFGpS) and constrained based flux balance analysis (FBA) to 
characterize and optimize glycoprotein synthesis. This platform will in the future allow us to 
robustly and systematically engineer novel glycosylation pathways. To approach that, we first 
developed a platform for enzymatically remodeling glycan structures on therapeutic relevant N- 
glycoproteins. This technology allowed us to have direct control of the glycoform and to 
produce homogeneous glycoproteins for structure- function relationship study. As a whole, we 
anticipated our mathematical and experimental approach could facilitate the fundamental 
understanding in glycoscience and could provide a novel approach for producing glycoprotein 
therapeutics.  
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CHAPTER 1 
INTRODUCTION TO GLYCOSYLATION AND FLUX BALANCE ANALSYSIS 
(FBA) 
1.1 Introduction: 
Glycosylation is one of the most common post translational modification (PTMs) on 
polypeptide chain in nature. The three main types of glycosylation, in which carbohydrate 
moieties are covalently attached to polypeptide chains are: N-linked glycosylation, O-linked 
glycosylation, and C-mannosylation glycosylation. Each type of glycosylation has glycans 
attach to the amide nitrogen of asparagine residues (N-glycosylation), to the hydroxyl oxygen 
of serine or threonine residues (O- glycosylation), and rarely to the indole C2 carbon of 
Tryptophan through C-C linkage (C-mannosylation) [1]. Among these three types of 
glycosylation, Asparagine- linked (N-linked) glycosylation is the most diverse and complex in 
structure and is one of the most frequent PTMs in eukaryotic cells. N-linked glycosylation is 
greatly involved in protein function, stability, folding, host-immune responses, and cell- cell 
and cell- virus interactions [2-4]. The importance of N-glycosylation is further reinforced as that 
more than 50% of the current protein-based therapeutics are N-linked glycoproteins [5]. As 
demands for recombinant monoclonal antibodies (rmAbs) products have increased significantly 
since 1986, many studies have done on studying and engineering mAbs [6-8]. An important 
finding is that correct glycosylation pattern can increase antibody or other glycoprotein stability 
and serum half- life, decrease its immunogenicity, and increase its binding affinity to antigens 
[9, 10]. Although many efforts have been made in the past decades to understand how 
glycosylation affects protein structure- function, the inability to precisely control glycan 
structures and the heterogeneity production have made it difficult [5]. 
Currently, mammalian based expression systems are preferable for glycoprotein therapeutic 
production in biopharmaceutical industry. Chinese Hampster Ovary (CHO) cells are by far the 
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most commonly used cell line [5]. It is involved in more than 70% of recombinant 
glycoconjugate therapeutics production, especially recombinant monoclonal antibody. CHO 
cells have the ability to produce properly folded protein with human- like glycoform, which is 
more likely to be compatible and bioactive in humans. They also have robust growth in serum- 
free suspension culture with substantial yield. Despite many advancements have been made in 
the past decades in engineering mammalian cell lines as platforms for producing glycoproteins, 
their endogenous glycosylation machinery makes it impossible to avoid glycoform 
heterogeneity leading to unwanted immune responses. This also makes the process of 
deciphering the effects of glycoforms on protein structure and function difficult [7, 11].  
The discovery of bacterial glycosylation pathways opens up potential avenue for scientists 
to engineer and produce homogeneous glycoproteins on demand. In early 2000s, bacterium N-
linked glycosylation was found in Campylobacter jejuni and its glycosylation gene cluster, pgl, 
was incorporated into Escherichia coli [2]. The ability to produce glycoproteins in E. coli has 
many advantages. Natively, E. coli lacks glycosylation machinery. Thus, by using E. coli as a 
host, we can avoid the possibility of introducing immunogenic epitopes produced by 
endogenous glycosylation pathway that mammalian cells have. Moreover, E. coli has a faster 
cell growth rate than mammalian cell lines. Since the incorporation of C. jejuni pgl pathway 
into E. coli, scientists have been able to use this system to engineer and produce proteins with 
various glycan structures attached [12-14]. Despite various in vivo expression platforms for 
glycoprotein synthesis are available, the inability to precisely control glycan structure of the end 
products has made it difficult to analyze the structure- function relationship of glycoproteins. In 
addition, the complex metabolic networks of cells have made the optimization of pathway 
challenging.  
System engineering approach has been utilized to understand and optimize metabolic 
pathways of cells toward maximizing recombinant product formation. Instead of manipulating 
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single element of the system, system biology studies the responses of microorganism to genetic 
changes using data and model-driven approaches. A wide range of simulation methods have 
been developed to analyze biological systems. These include kinetic approach that requires the 
knowledge of kinetic parameters of each enzyme, and stoichiometric approach that relies on 
stoichiometric matrix and constrains [15]. Shuler and coworkers pioneered in constructing large 
scale single cell models across multiple organisms that incorporated multiple catabolic and 
macromolecular synthesis pathways constrained by experimental kinetic parameters [16]. 
Unlike kinetic models, cybernetic model was first developed to predict microbial growth and 
behavior on multiple substrates and metabolic engineering strategies [17]. Although these two 
types of modeling strategies have been used widely and successfully in understanding and 
predicting metabolic changes, they are usually nonlinear systems that have complicated 
mathematics, and require a large set of experimental parameters that are expensive to 
implement.  
Constrained based flux balance analysis (FBA) is a widely used stoichiometric based 
mathematical approach to study genome wide metabolic network toward an optimal objective. 
FBA simplifies kinetic systems to simple linear algebraic system of mass balances.  This 
modeling strategy assumes the system is operating at pseudo- steady state [18, 19]. It is 
commonly implemented for in vivo system study and optimization, but as mentioned above, in 
vivo systems do not allow precise control of metabolite inputs; and, metabolites may be redirect 
to account for cell growth.  
Cell free protein synthesis (CFPS) technology, however, allows us to bypass the complex 
metabolic networks and growth factors within cells. CFPS is an in vitro protein production 
platform using biological machinery in a non-living cell environment [20]. This technology 
has been receiving growing attention as a tool for synthetic biology research and also for 
therapeutic production [21-23]. Today, it is a widely used tool for studying protein structure- 
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function relationship [20]. Therefore, in this work, we proposed to combine CFPS technology 
and mathematical approach, FBA, to understand metabolic networks involved in glycoprotein 
synthesis and to produce structurally- defined glycoproteins. To achieve that goal, we first 
aimed to develop an in vitro enzymatic glycan remodeling platform where we could produce 
homogeneous glycoproteins for structure- function relationship study. Then, we aimed to 
characterize the glycoprotein synthesis performance in our CFPS lysate systematically using 
FBA approach. 
 
1.2 Protein glycosylation 
N-linked glycosylation is one of the most essential and common PTMs found in eukaryotic 
cells. This process involves the synthesis of preassembled oligosaccharide(Glc3Man9GlcNAc2) 
in the lumen of endoplasmic reticulum (ER) of eukaryotes. Multisubunit enzymes called 
oligosaccharyltransferase (OTase) then catalyzes the transfer of the preassembled 
Glc3Man9GlcNAc2 moiety from the lipid carrier dolichyl pyrophosphate (Dol-PP) to an 
asparagine residue in the sequon Asn-X-Ser/Thr (N-X-S/T), of nascent polypeptide chains, 
where X is any amino acid residue except for proline [2, 3, 24]. 
Glycosylation is not only important in protein structure, function, stability, cell- cell and 
cell virus interaction, but its alternation can also lead to many diseases, such as cancer, cognitive 
disorder and mucosal diseases. This usually occurs when there is a change in glycosylation 
pattern or deficiency or overly producing of certain glycoform and enzymes. On many tumor 
cell surface, glycans are usually galactose terminated, which are suspected to be involved in the 
adhesion of metastatic cells [25]. The structure-function relationship present in diseases has 
potential for serving as therapeutic targets. But, despite many findings have identified glycan 
abnormal features of diseases, it is difficult to understand their mechanism and to find specific 
antibody [26].     
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1.3 Bacterial glycoengineering 
Although N- linked glycosylation was once thought to present only in eukaryotes, the 
existence of glycosylation pathways has been discovered and established in bacteria and archaea 
[27]. Among them, Campylobacter jejuni glycosylation pathway is one of the most well studied 
in bacteria. The glycosylation machinery in C. jejuni is encoded in a single gene cluster called, 
pgl. This functional pathway was transferred into E. coli and served as microbial expression 
platform for glycoprotein synthesis. In this system, a heptasaccharide, GalNAc- a1,4-GalNAc- 
a1,4- (Glc-b  1,3)- GalNAc- a1,4- GalNAc- a1,4- GalNAc- a1,3-Bac (where Bac is 
bacillosamine) is synthesized on lipid carrier undecaprenylpyrophosphate (Und-PP) at the 
cytoplasm. The heptassacharide is later flipped to the periplasm by a flipase, PglK.  Similar to 
eukaryotes, a C. jejuni OTase named, pglB, transfers the oligosaccharide onto an asparagine 
residue of a polypeptide that has a consensus sequence of D/E-X-N-X-S/T, where X is any 
amino acid except for proline. PglB has been shown to share similar structure as the eukaryotic 
OTase, Stt3. And, that both of these OTases are transmembrane proteins [1-3, 28]. The 
similarities between prokaryotic and eukaryotic glycosylation have motivated scientists to 
express proteins containing human-like or human- relevant glycoform in E. coli.  
One engineering example using E. coli based expression platform is the synthesis of 
Man3GlcNAc2 glycoform. This glycofom is significant because it is a common consensus 
glycan core structure in human N- glycans. Dr. DeLisa’s group has successfully produced and 
transferred Man3GlcNAc2 structure onto maltose binding protein (MBP) and single variant 
fragment antibody R4 (scFV13- R4) with a single C- terminal DQNAT glycosylation sequon 
via bacterial OTase pglB in E. coli. Although the efficiency was low, it has demonstrated 
possibility to engineer bacteria to express non-bacterial glycan structure [13].  
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1.4 Glycan remodeling technology 
Chemoenzymatic and chemoselective remodeling platforms are alternative methods for 
producing structure- defined glycoproteins with high specificity. Chemoenzymatic platform is 
an in vitro based system that utilizes a class of endoglycosidases (EnGases) to ligate free glycan 
and GlcNAc- tag- protein to form homogeneous glycoprotein. This technology requires the 
synthesis of intact oligosaccharides with oxazolines group that mimics the transition state of 
donor substrate. Later, endo-b-N- acetylglucosaminidase (ENGase) catalyzes trans- 
glycosylation to transfer preassembled oligosaccharide oxazolines onto GlcNAc – containing 
peptide or protein in a single step chemical reaction [29, 30].  
Chemoselective remodeling platform is another in vitro glycan remodeling platform. It 
utilizes site- directed mutagenesis in combination with chemical synthesis to introduce specific 
glycan structures onto protein. This strategy utilizes many different functional groups to 
facilitate formation of chemical bounds between protein and chemical synthesized glycan. One 
example is to introduce cysteine residue onto selected position of protein. The thiol group of 
cysteine residue is then reacted with glycol- methanethiosulfonate (glyco- MTS) reagents, and 
forms disulfide bond. Although both strategies are highly specific and can produce designed 
homogeneous glycoforms, they require synthetic chemical strategies, which can limit the 
complexity of glycan structure and can introduce chemical contamination [31].  
 
1.5 Cell free protein synthesis (CFPS) 
Cell free protein synthesis (CFPS) is a well-established and powerful technology for 
expressing proteins in cell lysate. CFPS has been used for decades as a research tools for 
fundamental and applied biology. Nirenberg and Mattaei used CFPS to decipher and elucidate 
the genetic code in 1961 [20, 32]. To date, CFPS is served as a tool for synthetic biology study 
and it is an emerging system for therapeutics production. Compared to in vivo protein 
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expression, CFPS has many advantages. CFPS produces proteins in cell lysate therefore 
decouples cell viability and production objective. Moreover, the absence of cell walls creates 
an open environment, which is convenient for direct monitoring, rapid sampling, and direct 
manipulation of protein production [33]. Another motivation for using CFPS is that it is portable 
and can produce desired therapeutics on demand. This system allows rapid production with a 
timeline of 1-2 days, whereas in vivo production usually takes about 1 week [21]. 
One important application of CFPS is that it has been successfully used for expressing 
membrane proteins in wheat germ, rabbit reticulocytes, and insect cells made lysate [34, 35]. 
However, in this study we aim to couple CFPS with in vitro glycosylation using E. coli based 
cell lysate to produce designer glycoproteins. E. coli lysate has many advantages such that it 
has low manufacturing cost, robust in high- pressure homogenizer, and rapid growth titer. Most 
importantly, E. coli lacks glycosylation pathway, which provides us a clean chassis for bottom-
up glycoengineering as well as avoiding possible contamination from native glycosylation 
machinery. 
Although CFPS has many benefits compared to in vivo expression systems, it is limited by 
its reaction size, product yield and efficiency. Because the production of CFPS depends largely 
on cell extracts, many studies have been made in optimizing cell extracts preparation and 
reaction conditions to overcome those obstacles. This opens up an opportunity to couple CFPS 
with mathematical models to study and optimize cell- free metabolism. 
 
1.6 Constrained based flux balance analysis (FBA) 
Constrained based flux balance analysis (FBA) is a widely used mathematical approach for 
studying biochemical networks, including genome scale networks [36]. Constrained based FBA 
uses linear programing method to predict productivity, yield, and mutant behavior for 
biochemical networks. This method is also a metabolic engineering method to identify the best 
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approach for producing desired products, such as chemicals and pharmaceutics. Constrained 
based FBA calculates metabolic fluxes across cells through deconstruction of metabolic 
networks into stoichiometric matrix under two assumptions: 1) The system must be at pseudo 
steady state. 2) the system is operating at its optimal to achieve a cellular objective. The problem 
is constrained by mass conservation equation and the upper and lower bounds of network 
metabolites. These constrains setup the allowable space for flux distribution (Figure 1.1). The 
next step of FBA is to setup a biological objective that the problem is interested in studying. 
Constraint based model is a powerful tool for estimating the performance of metabolic network 
using very few parameters [19, 37]. This method is a lot simpler than kinetic models that usually 
require kinetic parameters of enzymes and that the problem is usually non-linear. 
 
 
Figure 1.1 A schematic for constrained based flux balance analysis (FBA). S denotes for 
stoichiometric matrix and v denotes for metabolite fluxes. The unconstrained space is 
constrained by 1) the mass balance equation of metabolites and 2) the lower and upper bounds 
of metabolite fluxes. After an allowable space is defined, an objective needed to be defined in 
order to seek an optimal solution within the allowable space [19]. 
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CHAPTER 2 
THE DEVELOPMENT OF IN VITRO GLYCOPROTEIN REMODELING SYSTEM  
 
2.1 Introduction 
Glycosylation plays an essential role in eukaryotic cells. With incorrect glycoform, 
proteins tend to misfold, degrade, or can lead to diseases formation [38, 39]. Although many 
studies have done to engineer metabolic pathways in cells to produce designed glycoproteins 
[40, 41], heterogeneous glycofrom product cannot be avoided due to endogenous glycosylation 
pathways present in mammalian cells [42]. Some alternative methods are chemoenzymatic and 
chemoselective methods, which utilize chemical synthetic methods to produce preassembled 
glycan structures with functional groups and then attached to selected site through chemical 
reactions [29, 31, 43]. Despite these in vitro methods allow high specificity and homogeneous 
product formations, they are limited by the complexity of glycans that synthetic chemistry can 
produce. Therefore, herein we sought an alternative in vitro platform where we could bypass 
metabolic complexity of cells and also difficulties associated with chemical synthesis to produce 
homogeneous designed glycoproteins.  
In this enzymatic glycan remodeling platform, we aimed to engineer and express 
functional enzymes to modify model glycoproteins. The advantage to combine in vivo 
expression methods with in vitro glycan remodeling technology is that we could produce 
designed glycoproteins homogeneously and in large quantity. The first step of this process was 
to synthesize model glycoprotein precursors. Later, sequential enzymatic reactions were setup 
using the glycoprotein precursors to form desired glycoforms. The two glycan structure 
precursors were 1) GlcNAc and 2) Man3GlcNAc2. These two glycan structures were chosen 
because majority of N- linked glycans begin with GlcNAc carbohydrate. And, most of human 
N-linked glycoproteins share this Man3GlcNAc2 structure as their consensus core structure. By 
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having these two glycan structures as our model glycoprotein precursors, we had the potential 
to enzymatically elaborate on those glycan structures to a wide range of other N- linked 
glycoproteins. In this study, two glycoforms were focused: 1) a liner polysialic acid structure 
and 2) a biantennary structure. In figure 2.1, two glycosylation pathways of interest were shown. 
The first pathway begins with protein with single GlcNAc precursor and ends with a single 
polysialic acidd structure. The second pathway begins with Man3GlcNAc2 glycan structure and 
ends with a biantennary structure.  
 
 
 
Figure 2.1 Proposed pathways for in vitro glycan remodeling platforms. Product 1 is polysialic acid 
structure and Product 2 is biantennary structure. To synthesize Product 1, we utilized glycoprotein 
bearing single (GlcNAc) as our starting material, whereas for Product 2, we utilized glycoprotein bearing 
(Man3glcNAc2) glycan structure as out starting material. Enzymes involved in synthesizing these two 
pathways are N- acetylglucosaminyltransferases, 1) GntI and 2) GntII derived from Nicotiana tabacum 
and Homo. Sapiens, 3) b-1,4- galactosyltransferase from Homo sapiens, 4) 𝛂-2,3- sialyltransferase 
(CSTII) from C. jejuni, and 5) 𝛂-2,8- polysialyltransferase (PSTNM) from Neisseria meningitides. 
 
 
 
2.1.1 Production of linear polysialic acid-containing glycoprotein 
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Linear polysialic acid, 𝛂-2,8 linked sialic acid (PolySia) is a modification on many N-
glycans on specific cell surface proteins in central nervous (CNS) and immune systems. In CNS, 
PolySia is attached to neutral cell adhesion molecule (NCAM), where its hydrodynamic 
property inhibits cell- cell interactions [44]. Due to its large hydrodynamic volume, PolySia has 
been receiving as a potential “stealth polymer” for conjugation with protein drugs to improve 
therapeutics efficacy [45]. To synthesize proteins with linear polysialic acid, we utilized 
glycoprotein precursor with single GlcNAc. As proof of concept, we first employed already 
established in vivo expression method to express proteins, being glycosylated with 1) engineered 
Campylobacter lari glycan, (GalNAc4GlcNAc) in E. coli or 2) complex biantennary N-glycan. 
Next, we treated proteins having GalNAc4GlcNAc structure with exoglycosydase, 𝛂-N- 
acetylgalactosomine and antibody having biantennary structure with endoglycosidase S (Endo 
S) to trim down to single GlcNAc moiety (Figure 2.2). Proteins that were used in this study 
were single chain fragment variable R4 (scFv13 R4), human growth hormone variable, (HGHv), 
and Herceptin. Both scFv13 R4 and HGHv were purified from E. coli with GalNAc4GlcNAc 
structure and Herceptin was purified from mammalian cell line 293F with biantennary structure 
before enzymatic treatment. The reason for choosing these three proteins was to show the 
possibility to modify therapeutically relevant proteins using our method. And, later of the 
process, we aimed to show PolySia could effectively improve the stability of those proteins 
through serum half-life study.   
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Figure 2.2 A schematic for the synthesis of glycoprotein bearing single (GlcNAc) structure. Structure 3 is 
protein bearing GalNAc4GlcNAc purified from E. coli in vivo and can be trimmed down to single GlcNAc by using 𝛂-N- acetylgalactosomine. Structure 4 is antibody bearing biantennary structure, which can be trimmed down using 
EndoS.  
 
After obtaining protein precursors, enzymes needed for the pathways were identified 
from KEGG enzyme database. In figure 2.1, three enzymes were needed to synthesize Product 
1: b-1,4- galactosyltransferase from Homo sapiens, 𝛂-2,3- sialyltransferase (CSTII) from C. 
jejuni, and 𝛂-2,8- polysialyltransferase (PSTNM) from Neisseria meningitides. In this study, we 
specifically focused on proving the activity of CSTII and PSTNM. Activity of CSTII was verified 
using Alpha- 1 antitrypsin (A1AT), which had been shown as a protein substrate for CSTII [12]. 
Therefore, we decided to repeat the same experiment to show our CSTII also retain its activity. 
Activity of PSTNM was tested using GlcNAc-scFv13 R4 with the treatment of b-1,4- 
galactosyltransferase and CSTII. 
 
2.1.2 Production of biantennary glycoprotein 
One of the common human-like glycans is N-linked biantennary glycan structure. It is 
usually present on the Fc domain of antibody. Most of time, a fucose moiety is attached to the 
first GlcNAc of the biantennary structure, which has been shown to lower the binding affinity 
of IgG1 to the FcgIII receptor. Many studies have been made to engineer cell lines or additional 
treatment to produce antibody with afucosylated biantennary structure [10, 46]. Therefore, it 
!-N- acetylgalactosomine EndoSEndoS
3 4
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was in our interest to also synthesize therapeutic relevant proteins with afucosylated biantennary 
structure. To achieve that goal, we first expressed our glycoprotein precursor, Man3GlcNAc2- 
MBP- Glucagon, in E. coli based on already established method [47]. Unlike protein precursor 
with single GlcNAc, Man3GlcNAc2- MBP- Glucagon did not require additional treatment.  
Enzymes needed to form the biantennary structure (Product 2) shown in figure 2.1 included 
N- acetylglucosaminyltransferases, GntI and GntII derived from Nicotiana tabacum and 
Homo. sapiens, b-1,4- galactosyltransferase, CSTII and PSTNM. To synthesize biantennary 
structure, we decided to utilize protein with Man3GlcNAc2 structure, a consensus structure for 
human-like N-glycosylation, as our starting material. Because Man3GlcNAc2 structure does 
not exist in nature, it requires a lot of engineering work to be synthesize in E. coli. Currently, 
with the knowledge we have in the lab, we glycosylated MBP-Glucagon, a peptide hormone, 
with Man3GlcNAc2 structure in vivo in E. coli. Man3GlcNAc2-MBP-glucagon has also been 
shown to be a good substrate for GntI and GntII [47]. 
2.2 Results for bottom-up design of in vitro glycan remodeling platform 
2.2.1 Generation of N-linked glycoprotein precursor 
In an effort to produce high yield homogeneous N- linked designer glycoprotein, we 
employed previously developed methods to first produce N-linked glycoproteins in vivo in E. 
coli [12], then followed by in vitro treatments to remodel the glycan structure into designer 
glycofrom (Figure 2.1). This method allowed us to produce glycoprotein precursor of interest 
with a high yield and with minimal genetic engineering work. Specifically, two glycoprotein 
precursors were focused in this project: 1) protein bearing a single GlcNAc and 2) protein 
bearing Man3GlcNAc2 structure. As described in the introduction, many human- liked N-linked 
glycoproteins usually begin with a single GlcNAc or share a consensus Man3GlcNAc2 structure. 
Therefore, it was in our interest to generate these two glycoforms as our starting glycoprotein 
precursors for our in vitro remodeling platform. And later we aimed to use glycoprotein 
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precursor bearing GlcNAc to produce linear polysialic acid structure, and glycoprotein 
precursor bearing Man3GlcNAc2 to produce biantennary structure.  
Based on the in vivo glycoprotein synthesis methods developed previously, we 
expressed proteins bearing (GalNAc)4GlcNAc, Man3GlcNAc2, or biantennary glycan structure 
in E. coli strains: CLM24 or Origami 2 ∆nanA∆waaL∆gmd or in mammalian cell line: 293F 
(Figure 2.3). Protein bearing the later glycan structure, Man3GlcNAc, was directly used in the 
in vitro assays to synthesize biantennary structure. However, for proteins bearing either 
(GalNAc)4GlcNAc or biantennary structure additional treatment with exoglycosidase, a-N-
acetylgalactosaminidase, or endoglycosidase, EndoS, was required to produce glycoprotein 
precursors bearing GlcNAc (Figure 2.4). In this study, we were interested in investigating the 
structure and function relationship of therapeutically relevant proteins. Thus, we chose antibody 
fragment scFv13 R4 and human growth hormone variant (Hghv) as our model glycoprotein for 
synthesizing the linear polysialic acid structure, and MBP-Glucagon for synthesizing 
biantennary structure.  We were also interested in preparing antibody bearing GlcNAc as our 
glycoprotein precursor. This would be beneficial in creating a repertoire of different designed 
therapeutics relevant glycoproteins for structure- function relationship study.  
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 (a)         (b) 
 
(c) 
Figure 2.3 Glycoproteins bearing (GalNAc4GlcNAc) (a,b) and (Man3GlcNAc2) (c) expression detected by 
immunoblots. a) Weston blot for detecting GalNAc4GlcNAc-scFv13 R4 against histidine tag (up) and glycan serum, 
hr6p (down). G1 denotes for glycosylation band and G0 denotes for aglycosylated band. First lane was loaded with 
aglycosylated protein sample, and second lane was loaded sample with glycosylated sample. b) Weston blot for 
detecting GalNAc4GlcNAc-MBP-Hghv against histidine tag. There is no result for detecting against hr6p serum due 
to shortage on serum material. (c) Expression result for Man3GlcNAc2-MBP-Glucagon against histidine tag. The first 
lane contained aglycosylated MBP-Glucagon, whereas the second lane contained Man3GlcNAc2-MBP-Glucagon.  
Note: Antibody used in this study were either purchase commercially or obtained from Emily Cox.   
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  (a)       (b) 
Figure 2.4 Immunoblots for verifying the activity of EndoS and a-N-acetylgalactosaminidase. (a) Detection of 
aglycosylated, glycosylated and trimmed Herceptin against human IgG antibody. From left to right were in vivo 
purified Herceptin treated with PNGase F, in vivo purified glycosylated Herceptin bearing complex biantennary 
glycan structure, and trimmed glycosylated Herceptin by EndoS separately. (b) Detection of a glycosylated, 
glycosylated, and trimmed scFv13 R4 against histidine tag (up) and glycan serum hr6p (down). From left to right 
were in vitro purified aglycosylated scFv13 R4, in vitro purified GalNAc4GlcNAc-scFv13 R4, and GlcNAc-scFv13 
R4 after trimming. Note: there is no result here showing the trimming activity for GalNAc4GlcNAc-MBP-Hghv. It 
requires further experiments to consolidate the trimming data for GalNAc4GlcNAc-MBP-Hghv.  
 
 
2.2.2 Engineering and expressing glycosyltransferase- GntI, GntII, CSTII, and PSTNM 
To produce glycoform 1 and 2, several enzymes were selected to facilitate the in vitro 
remodeling process. N- acetylglucosaminyltransferase, GntI and GntII, transfer two GlcNAc 
onto Man3GlcNAc2; 𝛂-2,3 sialyltransferase, CSTII, transfers sialic acid onto glycoform bearing 
terminal galactose; 𝛂-2,8- polysialyltransferase, PSTNM polymerizes sialic acids onto glycoform 
bearing two terminal sialic acids. Most of the glycosyltransferases are known to be membrane 
anchor or membrane bound proteins.  Thus, in this study, GntI and GntII were engineered to be 
soluble by fusing each of them to mannose binding protein (MBP) and remove their membrane 
anchor region [47]. CSTII was optimized based on [48]. Although CSTII is also a membrane 
anchor protein, it has been shown to be partially soluble when expressed. PSTNM is also a 
membrane anchor protein. It was engineered by removing its 19 amino acids at the N-terminal 
and fused to MBP [49]. MBP-GntI and MBP- GntII were separately expressed in MC4100 and 
Origami2 ∆nanA∆waaL∆gmd::kan strains (Results not shown). CSTII and PSTNM were 
expressed in BL21(DE3) (Figure 2.5).  
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Figure 2.5 Immunoblots for detecting 𝛂-2,3 sialyltransferase, CSTII and 𝛂-2,8- polysialyltransferase, PSTNM 
fused to MBP against histidine tag. CSTII is about 34 kDa and MBP-PSTNM is about 61 kDa.  
 
2.2.3 Activity of N-acetylglucosaminyltransferases- GntI and GntII 
One focus of this work was to bioenzymatically synthesize complex biantennary glycan 
structure by using a common human N-linked intermediate glycan structure, Man3GlcNAc2, as 
our starting glycan precursor. To first test the activity of MBP-GntI and MBP-GntII, we supplied 
both of the enzymes into a reaction mixture where Man3GlcNac2MBP-glucagon UDP-GlcNAc 
were present. We observed a band shift detected by antibody against histidine tag via 
immunoblot for reaction containing MBP-GntI, but not MBP-GntII (Figure 2.6). To further 
confirmed the glycosylatransferases activity, we measured fluorescence generated by click 
chemistry method. In this experiment, we supplied MBP-GntI and MBP-GntII individually into 
different reaction mixture. We were only able to observe a band for reaction containing MBP-
GntI under fluorescence (Figure 2.7), but not for the reaction containing MBP-GntII (result not 
shown). These results indicated GlcNAc residues were transferred onto the terminal a-1,3 
mannoses successfully but not a-1,6. 
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Figure 2.6 Immunoblot for verifying the activity of MBP-GntI and MBP-GntII against histidine tag. Lane one 
contained in vivo purified MBP-Glucagon; lane 2 contained in vivo purified Man3GlcNAc2-MBP-Glucagon; and 
lane 3 contained GlcNAcMan3GlcNAc2-MBP-Glucagon.  
 
                            
Figure 2.7 In gel fluorescence detection for the activity of GntI using Man3GlcNAc2-MBP-Glucagon. In lane 
one, reaction contained all the materials needed to glycosylate Man3GlcNAc2-MBP-Glucagon into 
GlcNAcMan3GlcNAc2-MBP-Glucagon. The second lane did not contain enzyme, MBP-GntI, and lane three did not 
contain any protein.   
 
2.2.4 Activity of a-2,3-sialyltransferase- CSTII 
To synthesize either complex biantennary or linear polysialic aicd structure, we needed 
to install sialic acid onto galactose residue first as polymerase enzyme, PSTNM requiring 
minimally two sialic acid residues as its substrate. Hence, we utilized the a-2,3-sialyltransferase 
from C. jejuni called CSTII to remodel our glycoprotein to install sialic acids. CSTII has the 
activity to  transfer CMP-Neu5AC donor sugar onto a b-galactose acceptor sugar with an a-2,3 
linkage and also onto an a- linked sialic aicd acceptor sugar with an a-2,8 linkage. Before 
testing whether CSTII had the activity to transfer CMP-Neu5Ac onto a b-galactose acceptor 
sugar using either GlcNAc-scFv13 R4 or GlcNAc- MBP-Hgh as our model protein, we assessed 
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its activity by transferring CMP-Neu5Ac onto an a-linked sialic acid acceptor sugar using 
natural human alpha-1-antitrypsin, A1AT (abcam). The activity of CSTII was verified through 
click reaction and visualized by fluorescence under Alexa 488 (Figure 2.8).  
 
Figure 2.8 In gel fluorescence detection for the activity of 𝛂-2,3 sialyltransferase, CSTII using human alpha-
1-antitrypsin,A1AT, which has biantenarry structure attached. In lane one where there was an absence of both 
CSTII and CMP-N3-Neu5Ac, fluorescence was not detected. In lane two when A1At, CSTII, and CMP-N3-Neu5Ac 
were present in the reaction, fluorescence was detected. In lane three, the reaction lacked VMP-N3-Neu5Ac, 
fluorescence was again not detected.  
  
2.3 Discussion and future direction 
In this chapter, we have developed a platform to enzymatically remodel glycoproteins. 
The development of this platform included 1) generation of glycoprotein precursors 2) 
engineering and expressing glycosyltransferases in E. coli. 3) verifying the activity of 
glycosyltransferases through in vitro glycosylation activity assays. The enzymatic glycan 
remolding platform offers an opportunity to synthesize any desired N-linked glycoform 
homogeneously in vitro. This method avoids the presence of other glycoforms that usually occur 
in mammalian expression platform. Moreover, it bypasses the need to chemically synthesize 
glycan substrates, which was needed in chemoenzymatic and chemoselective remodeling 
platforms.  
Herein, we have demonstrated methods for producing glycoprotein precursors with 
single GlcNAc moiety and also with Man3GlcNAC2 by combining in vivo expression methods 
and in vitro trimming methods. This combine approach for producing glycoprotein with single 
kDa
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GlcNAc allowed us to generate glycoprotein precursors with large quantity that is usually not 
able to be achieved using in vitro platform. More importantly, this allowed us to synthesize any 
N-linked glycoprotein of interest. For Man3GlcNAC2 structure, although we could express 
Man3GlcNAC2-MBP-Glucagon with significant yield and modify it to form 
GlcNAcMan3GlcNAC2-MBP-Glucagon using our enzymatic remodeling platform, there was a 
limitation toward this process. Proteins are generally difficult to be glycosylated with 
Man3GlcNAC2 structure because it does not exist in nature. Until now, MBP- Glucagon is by 
far the only protein that can be glycosylated in high efficiency with Man3GlcNAC2 structure 
using the current E. coli based in vivo glycoprotein expression system. This limits our in vitro 
glycoprotein remodeling platform to have a variety of glycoprotein substrates bearing 
Man3GlcNAC2 structre. However, recently efforts have been made to improve the in vivo 
glycosylation efficiency for Man3GlcNAC2 structure using E. coli [50]. This indicates that there 
are potentials to improve expression level for glycoproteins bearing Man3GlcNAC2 structure 
and open up other potential glycoprotein candidates for our in vitro glycoprotein remolding 
platform.  
After the generation of glycoprotein precursors, we identified enzymes needed to 
produce polysialic acid structure and complex biantennary glycan structure using glycoprotein 
precursors either with single GlcNAc or with Man3GlcNAC2.  We were able to engineer and 
purify MBP-GntI, MBP-GntII, CSTII, and PSTNM in soluble form in E. coli. Later, by 
performing in vitro glycosylation reactions, we obtained positive signals for the activity assays 
of MBP- GntI, MBP-GnTII, and CSTII through either western blotting or click chemistry. 
However, the activity assay for CSTII appeared to have weak signal compared to the 
background signal. Further improvements on the design of CSTII could potentially enhance 
CSTII enzymatic activity. To further confirm their activity and the purity of products, more 
detailed study, such as mass spectroscopy or NMR will need to be carried out. Moreover, 
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enzyme kinetic analysis can assist our understanding of enzyme activity to optimize our in vitro 
glycosylation reaction conditions and to be incorporated into model designs. The final goal of 
this project was to produce homogeneous designed glycoprotesin that can be used for studying 
glycoprotein structure-function relationship. Thus, after all the analysis, we aim to utilize the 
glycoproteins synthesized using this in vitro glycan remodeling platform to study the effects of 
different glycoform have on protein folding, function, serum half- life, and cytotoxicity to the 
cells. Experimental studies such as X- ray crystallography, NMR can help elucidating those 
objectives.  
 
2.4 Methods 
2.4.1 Strains and plasmids 
E. coli strain DH5a was used for cloning and site- directed mutagenesis while strains 
CLM24, Origami2 p, MC4100 (araD139 D(argF-lac)205 flb-5301 pstF25 rpsL150 deoC1 
relA1), and BL21(DE3) (F- ompT hsdSB(rB- mB-) gal dcm(DE3)) were used for expressing 
different proteins used in this project. Glycoproteins, such as GalNAc4GlcNAc-scFv13 R4 and 
GalNAc4GlcNAc- MBP-Hgh were expressed in CLM24; Man3GlacNAc2-MBP-glucagon was 
expressed in Origami2 ∆nanA ∆waaL ∆gmd::kan. MBP- GnTI and MBP-GnTII were separately 
transformed and expressed in MC4100 and Origami2 (Novagen). CSTII and PSTNM were 
expressed in BL21(DE3). Plasmid pMAF10 encoding for C. jejuni pglB derived from pMLBAD 
vector and plasmid pACYC-pgl2 comprising lipid-linked engineered C. lari glycan- 
GalNac4GlcNac were co- transformed into CLM24. Later, they were transformed again with 
plasmid encoding for the protein substrate, either pBS R4DQNAT-6x His or pTrc-ssDsbA-MBP-
TEV-hgh-6xHis. As a negative control, plasmid pMAF10 was replaced with pMAF10 mutant, 
which lacks the oligosaccharyl transferase activity. Plasmid pYCG-pglB (from C. vulgaris) was 
used to produce lipid-linked Man3GlcNac2. This plasmid was co- transformed with pManCB-
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glucagon, which comprised of the linearized pMQ70 backbone and E. coli manB and manC 
genes. Genes encoded for GntI, GntII, PSTNM and CSTII were amplified from chromosomal 
DNA of Nicotiana abacum, Homo sapiens, Neiseria maningitidis, and Campylobactor jejuni 
separately. MBP-GntI and MBP-GntII constructs were kindly given by Glycobia [47]. 
Optimized CSTII gene [48] was cloned into PET28a with the digestion sties at NcoI and SalI. 
The construction of PSTNM gene was cloned from PET28a vector with a deletion of 19 amino 
residues at the N terminus, resulting an increase in solubility [49].  Gene PSTNMD19 was inserted 
into XbaI and HindII sites of pMAL-c4x vector with N- terminal 6x His tag.  
 
2.4.2 Expression and purification of model glycoprotein precursors 
E. coli strain CLM24 was chemically transformed with pMAF10/pMAF10 mutant, 
pACYC-pgl2 and pBS- R4DQNAT-6x His or pTRC99y MBP-hghv- 6xHis- NeuDBAC. 
Transformed cells were inoculate in a 10 mL LB. Cultures were grown at 37oC overnight 
containing 100 µg/mL trimethoprim (Tmp), 80 µg/mL spectrinomycin (Spec), and 20 µg/mL 
chloramphenicol (Cm) or 100 µg/mL ampicillin (Amp). The 10 mL overnight culture was then 
transferred into 1L LB and shacked at 37oC. At OD600 of 1.0, cells were induced with 0.2% 
(w/v) L-arabinose and 0.1 mM IPTG at 16-25oC for 16-20 hours. E. coli strain Origami2 ∆nanA 
∆waaL ∆gmd::kan carrying pYCG-pglB (from C. vulgaris) and pManCB-glucagon was 
inoculated in 10 mL LB containing 2% (v/v) glucose along with 20 µg/mL chloramphenicol 
(Cm)  and 100 µg/mL ampicillin (Amp) at 37oC. Overnight culture was then added to 1L TB 
supplemented with Cm and Amp and shacked at 37oC until OD600 reached 1.5. Culture was then 
induced with 0.2% (w/v) L-arabinose at 30oC for 12-16 hours followed by 4 hours induction by 
0.1mM IPTG the next day. Cells were harvested by centrifugation at 8,000 x g for 20 min at 
4oC and resuspended in 10 mL of Buffer A (50 mM HEPES, 250 mM NaCl pH 7.5) per 1 g of 
wet cell mass. Cells were then lysed by Avestin C5 EmulsiFlix homogenizer at 17,000 psi for 
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three passes. Lysed cells were centrifuged at 30,000 x g for 30 min at 4oC to remove cell debris. 
Soluble fraction was collected and rotated in 10 mM imidazole and 0.25 mL Ni- NTA resin at 
4oC for at least 1 hour. Sample was loaded into gravity column, washed with washing buffer 
(50 mM HEPES, 250 mM NaCl pH 7.5, 25 mM imidazole), and collected with elution buffer 
(50 mM HEPES, 250 mM NaCl pH 7.5, 300 mM imidazole). Protein was desalted using ZebaTM 
spinning desalting columns (ThermoFisher). Protein concentration was measured by Bradford 
assay (Bio-Rad).  
 
2.4.3 Expression and purification of GnTs, CSTII, and PSTNM 
E. coli strains MC4100, Origami were chemically transformed with either MBP-GnTI 
or MBP-GnTII. Both PET28a-CSTIIopt and MBP-PSTNMD19 were chemically transformed into 
E. coli strain BL21. Transformed cells containing GnTI, GntII, and PSTNMD19 were grown in 
10 mL LB containing 100 µg/mL ampicillin (Amp) at 37oC overnight separately. Transformed 
cells containing CSTII was grown in kanamycin (Km) at 37oC overnight. Cultures were 
transferred into 1L LB media the next day and shacked at 37oC until OD600 reached 1.0. Culture 
was then induced by 0.2% (w/v) L-arabinose for GnTs and 0.1mM IPTG for CSTII and PSTNM 
at 16oC for 16-20 hours. CSTII and PSTNM were purified following the same purification method 
described in section 2.3.2. Cells containing MBP-GnTI and MBP-GnTII, however, were 
resuspended in 10 mL MBP binding buffer (20 mM Tris-HCl, 1mM EDTA, 200 mM NaCl, pH 
7.4) per 1 g of wet cell mass. Resuspended cells were lysed by Avestin C5 EmulsiFlix 
homogenizer at 17,000 psi for three passes. Lysed cells were centrifuged at 30,000 x g for 30 
min at 4oC to remove cell debris. Soluable fraction was collected and incubated by rotation in 
4oC with 0.2 mL amylose resin for at least 1 hour. Later, sample was purified using gravity 
column and washed with MBP-binding buffer. Finally, protein was eluted with MBP elution 
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buffer (20 mM Tris-HCl, 1mM EDTA, 200 mM NaCl, pH 7.4, 10 mM maltose), and 
concentrated using 3K concentrator (ThermoFisher).  
 
2.4.4 Synthesis of GlcNAc precursor 
Synthesis of GlcNAc precursor, 1  µg of purified GalNAc4GlcNAc- R4DQNAT or 
GalNAc4GlcNAc-MBP- Hgh was treated with a-N- acetylgalactosominidase (New England 
BioLabs) following NEB’s protocol. The reaction was carried out at 37oC for 1 hour followed 
by 10 min heat deactivation at 65oC. Synthesis of GlcNac precursor was preliminarily 
determined by Weston blot against histidine tag and against hr6p, an anti- engineered C. lari 
glycan serum (from Aebi lab).  
 
2.4.5 Synthesis of GlcNac2Man3GlcNac2-MBP-Glucagon 
To produce GlcNac2Man3GlcNac2-MBP-Glucagon, 1-5  µg of purified Man3GlcNac2-
MBP-Glucagon was treated with 4  µg of MBP-GnT1 and MBP- GnT2 each and 2mM UDP-
GlcNAc or  0.02µg/mL of UDP-N3-GlcNAc in 20 mM HEPEs, 50 mM NaCl, 10 mM MsnSO4 
(pH 7.2) for 12 hours at 30oC. Product was detected by Weston blot against His tag. In addition, 
product produced by reacting with UDP- N3- GlcNAc was later used to perform click reaction 
and detected through fluorescence under Alexa 488 mode.    
 
2.4.6 Synthesis of (Neu5Ac)2 GlcNac2Man3GlcNac2-A1AT and (Neu5Ac)n(Neu5Ac)2 
GlcNac2Man3GlcNac2-A1AT 
(Neu5Ac)2GlcNac2Man3GlcNac2-A1AT was synthesized by reacting 1-5  µg of Alpha- 
1- antitrypsin (A1AT) with 0.012  µg/mL CMP- N3- Neu5Ac and 5  µg of purified CSTII in 50 
mM sodium phosphate (pH 8) and 10 mM MgCl2 at 37oC for 12 hours. Later, click reaction was 
performed to detect (Neu5Ac)2 GlcNac2Man3GlcNac2-A1AT under fluorescence. The product 
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was carried out to synthesize (Neu5Ac)n(Neu5Ac)2GlcNac2Man3GlcNac2-A1AT by adding the 
previous reaction into 2 mM CMP- Neu5Ac (or 0.012 mM CMP- N3- Neu5Ac ) and 5  µg of 
purified PSTNMD19, 50 mM sodium phosphate (pH 8) and 10 mM MgCl2. The reaction was 
carried out at 30oC for 12 hours. The final product was detected through SDS-PAGE or 
fluorescence.     
 
2.4.7 SDS-PAGE gel and Weston Blot  
SDS-PAGE analysis were performed with Bolt 8% and 10% Bis-Tris gel (Thermo 
Fisher Sceientific) and Mini-PROTEANÒ TGXTM 7.5%, 10%, and 12% Precast Gels in MOPS 
and SDS buffer accordingly. Most of the protein samples were boiled at 100oC for 10 minutes 
in 4x LDS protein dye with 10% 2-Mercaptoethanol, unless specified. For coomassie analysis, 
gels were stained with either R250 or G250 staining solution purchased from BioRad and 
destain with de-staining solution (water, methanol, and acetic acid in a ratio of 50/40/10 (v/v/v)) 
or deionize water. For Weston blot analysis, after gels finished running, they were transferred 
on to semi-transfer block or wet transfer block using membrane. Transferred image was block 
with 5% milk in TBST for minimally 30 minutes followed by 10 minutes washing step. 
Membranes were then incubated with antibody for one hour. Later, membranes were washed 
for 1 hour by changing TBST every other 10 minutes. If the samples did not require secondary 
antibody, they were imaged under Bio-Rad Molecular Imagerâ ChemiDocTM XRS+ imaging 
system; otherwise, samples would require to repeat the incubation and wash steps with the 
secondary antibody.    
 
2.4.8 Click Reaction  
Click reaction was performed on samples that used azido sugar as their donor sugar 
substrate for the in vitro glycosylation assay. After in vitro glycosylation reaction was 
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completed, samples were treated with 100 mM iodoaceamide (IAM) and shaked at low speed 
at room temperature in the dark. Then, 100  µM carboxyrhodamine 110 DBCO dye was added 
to the reaction and incubated at room temperature in the dark for one hour. During this step, 
carboxyrhodamine 110 DBCO dye would interact with the azidol group. The samples were then 
boiled at 65oC for 5 min in 4x LDS protein dye with 10% 2-Mercaptoethanol before loading on 
to SDS-PAGE gel (BioRad).  
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CHAPTER 3 
 
SEQUENCE SPECIFIC FLUX BALANCE ANALYSIS (SSFBA) ON 
GLYCOPROTEIN SYNTHESIS USING CELL FREE PROTEIN SYSTHESIS 
(CFPS) IN COMBINATION WITH IN VITRO GLYCOPROTEIN SYSNTHESIS  
 
3.1 Introduction 
Metabolic networks are described by intricate enzymatic and chemical reactions and 
are usually not optimized for producing desired products in practical applications [51]. System 
biology aims to understand and manipulate biological processes by studying the responses of 
microorganism to genetic changes through data and model- driven approaches [15]. The first 
mathematical model introduced by Jacques Monod successfully describe cell growth [52]. 
However, Monod’s model cannot handle situations when there is a change in environment [51]. 
Later, metabolic control analysis (MCA) was proposed by Kascer and Burns to analyze the 
effects of small change in enzyme concentration on flux distribution and intermediate 
concentrations of a metabolic pathway. MCA models require a priori knowledge of enzyme 
concentrations, which are difficult to acquire. Biochemical system theory (BST) was another 
mathematical theory attempted to describe metabolite changes. BST utilized rate constants as 
its sensitivity parameters, which involve power low expansions [53]. The experimental and 
mathematical difficulties involved in BST and MCA make them very expansive to compute. 
Cybernetic model describes microbial responses under multiple substrates environment in 
synthesizing multiple proteins under optimal condition [54]. The advantage of cybernetic 
network over MCA and BST is that it is able to adjust to environmental perturbation; however, 
this approach utilized only abstract models of the network.   
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As understanding of biology systems grew, metabolic networks also become more 
sophisticated. One of the pioneering whole cell models constructed by Shuler and coworkers 
was to understand cell growth in glucose minimal medium environment [16]. Since then, models 
have been developed to study various cells under various culture conditions. Although many of 
those models have shown to be successful, the difficulties involved in obtaining experimental 
data and the complexity involved in non-linear computation make them computational 
expansive.  
Constraint based flux balance analysis (FBA) unlike kinetic models is a linear 
programing method based on stoichiometric matrix, flux constrains, and an objective function 
[19]. FBA models have been applied to design engineered strains to overexpress metabolites 
through alternating metabolic flux distribution. It is also utilized to rationally develop cell 
culture medium [18, 55]. All the FBA applications mentioned above share a common goal- to 
seek an optimal condition where cells can grow under minimal stress and can enhance product 
formation. FBA has been used in developing bacterial strain for biofuel and pharmaceutics 
production [56, 57]. An expansion on FBA has been developed to incorporate transcription and 
translation reactions for specific DNA and protein sequences. This modeling method is called 
sequence specific flux balance analysis (ssFBA). Both FBA, ssFBA, and other variants of FBA 
have been expanded into genome-scale and can capture the regulatory effects on change in 
metabolism [58]. FBA has been utilized mainly to study regulatory performance in in vivo 
system. But, as mentioned in chapter one and two, the “black- box” nature of in vivo systems 
has made it challenging to understand and rewire the metabolic networks of cells. Therefore, 
we sought an in vitro platform where we could study and understand the metabolic changes 
under different growing conditions. In particular, we utilized ssFBA to analyze metabolite 
fluxes of cells.  
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Cell free protein synthesis (CFPS) is an in vitro system for expressing proteins in non- 
living cell environment, which allows us to bypass metabolic burden on cell growth and allows 
direct control of metabolites [59]. CFPS has been receiving growing attention as a tool for 
synthetic biological research due to its open environment without interference of cell wall and 
cell growth and its ability for direct metabolite control. It has been used as a tool for deciphering 
genetic code, a method for incorporating unnatural amino acids into proteins, and a high- 
throughput method for screening labeled- protein functions [60-62]. Despite CFPS has many 
disadvantages in terms of its yield, expenses, and reaction size, many advancements have been 
made to improve CFPS system. It has been considered as a novel platform for producing 
therapeutic proteins in industrial size and quality [63, 64]. More recently, researchers have 
started to couple CFPS with in vitro glycosylation reaction to produce glycoproteins [33]. The 
open environment cell free protein glycoprotein synthesis offered allows us to interrogate the 
chemical environment and identify the genetic manipulation needed for producing desired 
glycoprotein.  
In Chapter two, we demonstrated an in vitro glycoprotein remolding platform. To 
further understand and analyze protein synthesis to create a platform for homogeneous designed 
glycoprotein production, we aimed to produce proteins using CFPS and implemented a 
mathematical model to analyze change in metabolites for protein expression as a proof of 
concept in this chapter. We chose super folded green fluorescence protein (sfGFP) as our model 
protein and expressed it in CFPS. We implemented our mathematical model, ssFBA, to analyze 
change in metabolites at different time points. A core E. coli metabolic model, describing 
glycolysis, pentose phosphate pathway, energy metabolism, amino acid biosynthesis, and 
degradation was implemented into the model. The incorporation of amino acid synthesis and 
degradation augmented FBA to describe specific transcription and translation processes with 
specific promoter. In particular, we studied two cases, 1) a constrained case where the bounds 
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were limited by experimental data, and 2) an unconstrained case where there was no restriction 
set on the bounds.   
 
3.2 Results- ssFBA on the synthesis of GalNac4GlcNAc-sfGFP using CFPS following by in 
vitro glycoprotein synthesis 
3.2.1 Validation of model predictions 
Super folded green fluorescence protein (sfGFP) was expressed in CFPS under T7 
promoter using PEP as the carbon and energy source. After the protein was expressed in CFPS, 
in vitro glycosylation reaction was directly performed. sfGFP was then glycosylated with 
(GalNAc4GlcNAc) structure. Metabolites were quantified by LC-MS methods. Due to 
inconsistency between each sample preparation, some experimental data was optimized by 
removing some of those outliers. Mean and standard deviations were recalculated after 
optimization and those were the data used in our ssFBA model. In this study, proteins were only 
translated for 20 minutes in order to reach the maximum glycosylation efficiency. Samples were 
quenched at four different time points and at each time point, there were three duplicates.  
We validated our ssFBA model with the experimental measurements obtained from LC-
MS. We specifically measured 20 organic acids, but only 11 of those were implemented in our 
ssFBA model to constrain to bounds. For the constrained case, the problem was set up to 
evaluate the data from 0 to 10 minutes followed by another calculation from 10 to 20 minutes 
based on the trends observed from the experimental data. Figure 3.1 shows a panel of 11 
metabolites including experimental data, simulation for constrained and non-constrained cases. 
Most of the simulations for the constrained case behaved in similar trends as the experimental 
data. Especially, the experimental data for GAP, PEP, pyruvate, and malate fell in the 95% 
interval region of the simulation. However, the mathematical simulation did not correlate well 
with some of the metabolite, such as fumarate, glutamate, lactate and acetate.  
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(a)                    (b) 
 (c)                    (d) 
 (e)                    (f) 
  (g)                   (h) 
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 (i)                      (j) 
 (k) 
Figure 3.1 A panel of 11 metabolites concentration over 20 minutes CFPS reactions. Experimental data is 
denoted with black dots with error black bars. Red line denotes for the unconstrained case. Black line denotes for the 
constrained case. The blue shaded area represents the calculated 95% confidence interval for the constrained case. 
Each of the graph represents the concentration change over 20 minutes interval. From (a)-(k) is data 3GP, GAP, PEP, 
pyruvate, succinate, fumerate, glutamate, glycerol-3-phosphate, lactate, acetate, and malate.  
 
3.2.2 Analysis of the CFPS performance 
 In order to understand the performance of our CFPS system, we analyzed the carbon 
yield and energy efficiency for constrained and unconstrained cases. The carbon yield for the 
constrained case from 0-10 minutes was 7.3% and 9.6% from 10-20 minutes, whereas the 
carbon yield for the unconstrained case was 96.9%. In figure 3.2, the carbon yield distribution 
was illustrated in pie charts format. As seen in Figure 3.2, in the unconstrained case (Figure 3.2 
(a)), there was a 54.3% accumulation of sfGFP, whereas in the unconstrained case, from 0-10 
minutes, there was 81% succinate accumulation; and from 10-20 minutes, there was about 52% 
of fumarate accumulation. This indicates that for the first 20 minutes of cell free protein 
synthesis, most of the carbons were spent on making organic acid byproducts.  
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   (a)         (b) 
 (c) 
Figure 3.2 Pie charts for carbon yields. (a) is for the unconstrained case. (b) is for the experimental constrained 
case from 0-10 minutes. (c) is for the experimental constrained case from 10- 20 minutes.  
 
 Another parameter used to analyze the CFPS performance was energy efficiency. 
Energy efficiency was analyzed by different metabolite reaction groups, including glycolysis 
(gly), amino acids synthesis (AA), anapleoretic (ana), chorismate (cho), energy degradation 
(en), and protein synthesis (prot). In the unconstrained case, the maximum energy efficiency 
was 100%. For constrained case, the maximum energy efficiency spent on protein synthesis was 
about 74% ± 15% from 0 to 10 minutes and 12% ± 3.5%. In order to investigate where the 
energy was spent on, we then looked into the energy efficiency for each of the categories listed 
above. For the first 10 minutes of the reaction, 74% of energy was spent on protein synthesis 
and 22.8% was spent on glycolysis. But after the first 10 minutes, 68% of the energy was spent 
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on energy degradation, 18.7% was spent on glycolysis, and only about 12.6% was spent on 
protein synthesis (Figure 3.3). 
 (a)   (b) 
 (c) 
Figure 3.3 Pie charts for demonstrating the energy efficiency spent on the following metabolic reactions: 
glycolysis (gly), amino acids synthesis (AA), anapleoretic (ana), chorismate (cho), energy degradation (en), and 
protein synthesis (prot). (a) is for the unconstrained case. (b) is for experimental constrained case from 0-10 minutes. 
(c) is for the experimental constrained case from 10-20 minutes.  
 
3.3 Discussion and future direction 
 In this chapter, we were able to synthesized sfGFP using CFPS and utilized the 
metabolites data to implement ssFBA model specifically describing sfGFP synthesis. For most 
of the metabolites, we were able to show close correlation between the experimental constrained 
simulation and the experimental data. However, there were some cases where the experimental 
data fell out of the calculated 95% interval. This can be due to experimental error, but further 
analysis will require to better train the model to predict sfGFP production.  
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 Based on the analysis of the CFPS production, we noticed that most of the carbon was 
spent on succinate production in the first 10 minutes. And from 10 to 20 minutes, most of the 
carbons was spent on fumarate production. From the energy efficiency data, most of the energy 
was spent on protein synthesis in the first 10 minutes with a portion of energy spent on 
glycolysis. However, from 10 to 20 minutes, most of the energy was spent on energy 
degradation reactions. Usually transcription and translation will require about 10 to 12 hours. 
The reason we only setup our CFPS reaction for 20 minutes was based on previously observed 
trend by the DeLisa group that sfGFP could achieve highest glycosylation efficiency when 
CFPS reaction only occurred for 20 minutes. And, based on the result seen in chapter 3, further 
analysis can be done to further deciphering where the energy spent on and where the carbons 
are directed to form during different time points. This study can in the future help engineering 
E. coli cell lines to improve glycoprotein production. 
 
 
 
   
3.4 Method 
3.4.1 Cell free protein synthesis  
CFPS reaction was performed using the S30 cell extract in a total volume of 15 µL. The 
S30 cell extract was prepared using BL21(DE3) cell line. The reaction mixture contained 
1.2mM ATP, 0.85 mMof GTP, UTP, and CTP each, 34.0 µL/mL L-t-formyl-5,6,7,8 
tetrahydrofolic aicd (folinic acid), 179.9 µL/mL of E. coli tRNA mixture, 130 mM potassium 
glutamate; 10 mM ammonium glutamate, 12 mM magnesium glutamate, 2mM of each 20 amino 
acids, 10 µM of L-[14C(U)]-leucine, 0.33 mM nicotinamide adenine dinucleotide (NAD), 0.27 
mM coenzyme-A (CoA), 1.5mM spermidine, 1mM putreschine, 4mM sodium oxalate, 33mM 
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phosphoenolpyruvate (PEP), 250 ng of sfGFPDQNAT plasmid, 100 µg/mL T7 RNA polymerase 
and 27% v/v of cell extract. Cell free protein synthesis reactions were carried out at 30oC for 0, 
5, 10, and 20 minutes in triplicates. Translation only happened for 20 minutes was to be able to 
reach maximum glycosylation efficiency.  
 
3.4.2 In vitro glycosylation reactions 
After CFPS were completed, they were carried out to perform in vitro glycosylation at 
30oC for two hours. The final volume of the in vitro glycosylation reaction was 20 µL with 15 
µL of CFPS, 2 µL of reaction buffer (10 mM HEPES, pH 7.5, 10 mM MnCl2, and 0.1% (w/v%) 
DDM ), and …. PglB.  
 
3.4.3 Constrained based sequence specific flux balance analysis 
Constrained based sequence specific flux balance analysis (ss- FBA) was used here to 
understand the performance of E. coli based cell free glycoprotein synthesis. This method 
coupes transcription and translation reactions into metabolic network. A core E. coli cell free 
stoichiometric network describing glycolysis, pentose phosphate pathway, energy metabolism, 
amino acid biosynthesis and degradation was developed from the iAF1260 reconstruction of K-
12 MG1655 E. coli. This network contains 264 reactions and 146 species. In this problem, our 
model glycoprotein was GalNAc4GlcNAc-sfGFPDQNAT.  FBA method requires two 
assumptions. First, cells must operate at pseudo steady state. Second, the cells must operate 
optimally to satisfy an objective. The problem then can be setup by decomposing the metabolic 
network into stoichiometric matrix following by linear programming problem: 
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where c is the objective vector, S represents the stoichiometric matrix of metabolites with each 
row describing one metabolite and each column describing a metabolic reaction, and n denotes 
metabolic flux vector where a and b are the lower and upper bounds for the individual flux 
values. The problem was setup to maximize the rate of protein translation. In stoichiometric 
matrix, each element is denoted by sij. When sij>0, species i is produced by reaction j, whereas 
when sij<0, species i is consumed by reaction j. In the case when sij = 0, species i does not 
participate in reaction j. To account for transcription in the network, additional constraints on 
transcription and translation are required. The bounds on the transcription rate was modeled as:  
 
where wx is the transcription rate; Gp denotes the concentration of the gene encoding the protein 
of interest; and, Kx denotes the transcription saturation coefficient. The maximum transcription 
rate 𝑉#$%# was calculated by: 
 
where RT denotes the RNA polymerase concentration (nM), Vx denotes the RNA polymerase 
elongation rate (nt/hour), and IG is the gene length (nt). The effective function of promoter 
activity, u(k) (dimensionless, 0<u(k)<1) was taken from Moon et al, where k denotes promoter 
specific parameters. In this study we utilized T7 promoter. The promoter function for the T7 
promoter, uT7, was given by: 
max
υ1....υR
ciν i
i=1
R
∑
Sυ = 0
Li ≤ Sijυ j ≤Ui
j=1
R
∑
α j ≤υ j ≤ β j
ωx =Vxmax (
G p
Kx +Gp
)
Vxmax = [RT (
Vx
IG
)u(k))]
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where KT7 denotes T7 RNA polymerase binding constant.  
The translation rate (wT ) was bounded by: 
  
where mRNA* represents the mRNA aboundance, and KT represents a translationa saturation 
constant. The maximum translation rate 𝑉&$%# was calculated by:  
 
where KP denotes the polysome amplification constant, nT denotes the ribosome elongation rate 
(amino acid per hour), and lP denotes the number of amino acids in the protein of interest.  
 
3.4.4 Calculation of energy efficiency 
Energy efficiency (E) is calculated as the ratio of protein production to glucose 
consumption. They were formulated in terms of equivalent ATP molecules:  
 
 
where ATPT, GTPT, CTPT, UTPT represent the stoichiometric coefficients of energy species for 
the transcription of the protein of interest; ATPX, GTPX represent the stoichiometric coefficients 
of ATP and GTP for the translation of the protein of interest, qGLC denotes for glucose uptake 
rate, and ATPGLC denotes the equivalent ATP number produced per glucose.    
 
 
uT 7 =
KT 7
1+KT 7
0 ≤ωT ≤VTmax (
mRNA*
KT +mRNA*
)
VTmax = KPRT (
υT
lp
)
E = ωX (2× ATPX +GTPX )+ωT (ATPT +GTPT +CTPT +UTPT )qGLC × ATPGLC
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3.4.5 Calculation of carbon yield 
Carbon yield (𝑌()*+) was calculated as the ratio of carbon produced as the protein of 
interest divided by the carbon consumed as reactants (glucose and amino acids):  
 
where qPOI denotes the flux of the protein of interest produced, CPOI denotes carbon number of 
the protein of interest, R denotes the number of reactants, qmi denotes the uptake flux of the ith 
reactant, and Cmi denotes the carbon number of the ith reactant.  
 
3.4.6 Calculation of maximum and minimum bound for fluxes 
At each time point, a minimum and a maximum were obtained by subtracting or adding 
the standard deviation to the actual data point: 
 
The upper bound and lower bound of each metabolite was calculated based on the following 
equations: 𝑙𝑜𝑤𝑒𝑟	𝑏𝑜𝑢𝑛𝑑 = 78,:;<=7>,:?@#8,:;<=#>,:?@  𝑢𝑝𝑝𝑒𝑟	𝑏𝑜𝑢𝑛𝑑 = 𝑙𝑜𝑤𝑒𝑟	𝑏𝑜𝑢𝑛𝑑 + (	𝑦E,$%# − 𝑦G,$HI𝑥E,$%# − 𝑥G,$HI − 𝑙𝑜𝑤𝑒𝑟	𝑏𝑜𝑢𝑛𝑑)×𝑟𝑎𝑛𝑑𝑜𝑚 
where x represents time and y represents metabolite concentration.  
 
3.4.4 Quantification of organic acids 
The protocol for quatifying organic acid was taken from ….(paper) with some 
modification on cone voltages.  
 
YCPOI =
qPOI *CPOI
qmi ×Cmi
i=1
R
∑
max = [metabolite]+ stdv.
min = [metabolite]− stdv.
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LC-MS system:  
The LC-MS system consisted of a UPLC system (Acquity H-Class, Waters) and a source mass 
spectrometer (QDA detector, Waters). This system was controlled by Empower 3 software 
(Waters). Seperation was performed on a Acquity CSH C18 Column (2.1mm x 150 mm, 
Waters).  
Solvent A: 5mM tert- butylamine (TBA) aqueous solution adjust pH to 5.0 with acetic acid. 
Solvent B: 5 mM TBA in 100% acetonitrile. 
 
1. Light labeling reagent: 6M 12C6-aniline solution (pH 4.5) by mixing 5.500 mM of 
aniline with 2.250 mL of water and 2.250 mL ofconcentrated hydrochloric acid (HCl). 
Vortex well and measure pH. If ecessary adjust pH with HCl. The solution can be stored 
at 4oC for up to 2 months.  
 
2. EDC solution: N-(3-dimethylaminopropyl)-N’- ethylcarbodiimide hydrochloric 
(200mg/mL) dissolved in Milli-Q water.  
 
3. Triethylamine (TEA) 
Sample solution consisted 5 µL of quenched CFgPS reaction and 95 µL of autoclaved H2O 
in 1.5 mL Eppendorf tube. 10 µL of EDC solution was added into the sample solution. Vortexed 
aniline solution until it was well mix before adding 10 µL into the sample preparation. Reaction 
mixture was incubated on rocker at low speed at room temperature for 2 hours. Then, 2-5 µL of 
TEA was added to the sample solution  and centrifuged at 13,500xg for 2 min. Transferred the 
aqueous portion of the sample into an auto- sampler vial.  
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LC- MS setup: 
Starting up by setting an elution gradient from 5- 70% Solvent B over 4 min, further 
increase to 100% Solvent B in 0.5 min, and held at 100% Solvent B for 2.5 min. Flowrate was 
set at 0.3 mL/ min with injection volume of 1 µL. Column was preconditioned by pumping the 
starting mobile phase mixture for 10 min. LC-MS chromatograms were acquired in negative ion 
mode under the following conditions: capillary voltage of 15 V, dry temperature at 520 oC, and 
an acquisition range of m/z 100-800.  
 
3.4.5 Quantification of amino acids   
A solution containing a mixture of 19 amino acids is drivatized with Waters AccQ-
Tawq Ulta amino acid analysis kit (Waters). Sample was prepared by adding 80 µL amino acids 
(Amino Acid H- Standard, Waters) with 10 µL of buffer solution (Waters) followed by 10 µL 
of reagent (Waters). The reaction mixture was incubated at 55oC fo 10 min. Later the sample 
was separated by UPLC with an Acquity Amide C18 Column (2.1 mm x 150 mm, Waters) and 
analyzed with a TUV detector at 260 mm. Amino acid s were detected and quantified based on 
known retention times.  
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